PubMed RSS Feed - -Brimonidine gel for the treatment of recalcitrant facial erythema in diseases other than rosacea: a novel tool for clinicians.

[rss]

Brimonidine gel for the treatment of recalcitrant facial erythema in diseases other than rosacea: a novel tool for clinicians.

J Eur Acad Dermatol Venereol. 2016 Mar 16;

Authors: Del Barrio-Díaz P, Moll-Manzur C, Vera-Kellet C

Abstract
BACKGROUND: Clinicians have recognized the impact of cutaneous signs and symptoms in patient's quality of life over the years. Often, systemic response to a certain therapy is faster than the cutaneous response, leading to patient frustration and treatment discontinuation. Brimonidine gel is an alpha-2 adrenergic agonist recently approved by the FDA for the treatment of persistent facial erythema of rosacea.
OBJECTIVES AND METHODS: We describe 3 patients with recalcitrant facial erythema secondary to dermatomyositis, pityriasis rubra pilaris and systemic lupus. Their main complaint was facial erythema that was persistent even though they were under systemic treatment. Empirically, we decided to try topical Brimonidine gel for the treatment of their facial erythema as a rescue measure.
RESULTS: 30 minutes after we applied 0.5% Brimonidine gel in the office, we achieved an excellent clinical response, without adverse effects in all of these patients.
CONCLUSION: Topical Brimonidine gel may be a complementary therapy for the management of recalcitrant facial erythema in patients with systemic lupus, dermatomyositis and pityriasis rubra pilaris.

PMID: 26990727 [PubMed - as supplied by publisher]

{url} = URL to article